ELIZABETH WILLENS: Open Payments
NPI 1649965633 · LENEXA, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$790 in 52 payments from 13 companies in 2025. Trend: 2023 $699 · 2024 $866 · 2025 $790
Food & beverage: $783Education: $8
| Company | Payments | Amount |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 16 | $176 |
| ABBVIE INC. | 14 | $172 |
| Otsuka America Pharmaceutical, Inc. | 5 | $93 |
| Alkermes, Inc. | 3 | $70 |
| E.R. Squibb & Sons, L.L.C. | 3 | $62 |
| Vanda Pharmaceuticals Inc. | 2 | $44 |
| Teva Pharmaceuticals USA, Inc. | 2 | $33 |
| Axsome Therapeutics, Inc. | 2 | $29 |
| Neurocrine BioSciences, Inc. | 1 | $25 |
| Lundbeck LLC | 1 | $25 |
Products named: VRAYLAR, Qelbree, REXULTI, COBENFY, ARISTADA, HETLIOZ, ABILIFY MAINTENA, AUSTEDO XR.
Industry payments across KS — which companies pay providers there.
